Tick-borne encephalitis virus neutralization by high dose intravenous immunoglobulin
Language English Country Netherlands Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
27884572
DOI
10.1016/j.ttbdis.2016.11.007
PII: S1877-959X(16)30215-1
Knihovny.cz E-resources
- Keywords
- Antibody-dependent enhancement, Flavivirus, IVIG, Immunotherapy, Neutralizing antibodies, Ticks,
- MeSH
- Glioblastoma virology MeSH
- Immunoglobulins, Intravenous administration & dosage MeSH
- Encephalitis, Tick-Borne therapy MeSH
- Humans MeSH
- Mice MeSH
- Cell Line, Tumor MeSH
- Neuroblastoma virology MeSH
- Encephalitis Viruses, Tick-Borne drug effects MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Immunoglobulins, Intravenous MeSH
Tick-borne encephalitis (TBE) is a potentially lethal neuroinfection in humans, caused by TBE virus (TBEV). Currently, there are no approved therapeutic agents to treat TBE. Previously, it was suggested that application of high dose intravenous immunoglobulin (IVIG) may pose potentially successful treatment for severe cases of TBE. In this study, we determined the titers of TBEV-neutralizing antibodies in two IVIG lots originating from the same manufacturer, and tested their ability to treat a lethal TBEV-infection in a mouse model. Using an in vitro assay, more than 100-fold difference in TBEV-neutralizing capacity was demonstrated between the two individual IVIG lots. High TBEV-neutralizing activity of IVIG containing TBEV-specific antibody was confirmed in two different human neural cell lines, but IVIG without TBEV-specific antibodies had no or little effect on virus titers in the culture. In TBEV-infected mice, 90% of protection was achieved when the mice were treated with IVIG containing higher titers of TBEV-specific antibodies, whereas no immunotherapeutic effect was seen when mice were treated with IVIG without TBEV-specific antibodies. No antibody-dependent enhancement of TBEV infectivity induced by cross-reactive antibodies or by virus-specific antibodies at neutralizing or sub-neutralizing levels was observed either in cell culture or in TBEV-infected mice treated with any of the IVIG preparations. The results indicate that IVIG lots with high TBEV antibody titers might represent a post-exposure prophylaxis or first-line effective therapy of patients with a severe form of TBE.
Department of Virology Veterinary Research Institute Hudcova 70 CZ 62100 Brno Czechia
Faculty of Science University of South Bohemia Branisovska 31 CZ 37005 Ceske Budejovice Czechia
References provided by Crossref.org
History of Arbovirus Research in the Czech Republic
Structure of tick-borne encephalitis virus and its neutralization by a monoclonal antibody